Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-acetylcysteine + silibin is a combination of two active compounds—N-acetylcysteine (NAC), a well-established mucolytic and antioxidant agent, and silibin (also known as silybin or silibinin), the major active flavonolignan component of silymarin extracted from milk thistle. NAC acts primarily by replenishing intracellular glutathione stores, directly scavenging free radicals, breaking disulfide bonds in mucus to reduce viscosity, and providing hepatoprotective effects especially in acetaminophen overdose[1][2][3][6]. Silibin is known for its antioxidant, anti-inflammatory, and hepatoprotective properties; it inhibits lipid peroxidation and modulates cell signaling pathways involved in inflammation and fibrosis. The combination is used primarily for liver protection—especially in cases of acute toxic liver injury such as Amanita phalloides (death cap mushroom) poisoning—and may be considered for other indications where both antioxidant support and hepatic protection are desired.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-acetylcysteine + silibin.